Skip to main content

Table 3 Summary of characteristics of patients with pneumonitis

From: Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors

Patient characteristics

Age, Median (range)

69 (53–81)

Sex, Male/Female

17/2

Smoking history

Current/Former/Never

6/10/3

Amount of smoking (pack-years)

Median (range)

36.75 (0–190)

Tumor

HNC/MM/GC/RCC/UC

6/1/3/3/6/3

BMI(kg/m2), Median (range)

20.08 (14.61–32.326)

Immunotherapy, NIVO/PEM

16/3

ILD, Yes/No

4/15

LM, Median (range)

14/5

Treatment line, Median (range)

3 (1–5)

TKI, Yes/No

5/14

CRP(mg/dl), Median (range)

0.79 (0.08–10.49)

NLR, Median (range)

4.46 (0.77–11.36)

OP/NSIP/OP + NSIP/HP

9/6/3/1

  1. C Current, BMI Body mass index, F Female, F former, GC Gastric cancer, HNC Head and neck cancer, HP Hypersensitivity pneumonitis, ILD Interstitial lung disease, LM Lung metastasis, M Male, MM Malignant melanoma, N Never, NLR Neutrophil-to-lymphocyte ratio, NIVO Nivolumab, NSIP nonspecific interstitial pneumonia, OP Organizing pneumonia, PEM Pembrolizumab, RCC Renal cell carcinoma, TKI Tyrosine kinase inhibitor, UC Urothelial carcinoma